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Abstract Genetically engineered animals carrying defined 
alterations in their genome can represent invaluable tools for 
better understanding complex polygenic diseases such as non-
insulin-dependent diabetes mellitus (NIDDM) at the molecular 
level. The structure or expression of a number of genes 
potentially involved in insulin action or pancreatic ß-cell function 
have recently been altered in the mouse using transgenic or gene-
targeting approaches. The obtention of such mice is the first step 
towards the development of animal models carrying multiple gene 
defects which would be very useful in NIDDM research. 
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1. Introduction 
Non-insulin-dependent diabetes mellitus (NIDDM) affects 
several million people world-wide and is characterized by in-
sulin resistance as well as ß-cell dysfunction. Insulin resistance 
is also found associated with many disorders other than 
NIDDM. Several recent reviews have focused on various as-
pects of NIDDM (review [1] and refs. therein). This review 
attempts to summarize the recent application of transgenic 
and gene-targeting approaches to develop mouse models use-
ful for NIDDM research. 
1.1. Insulin secretion and action 
Insulin is a polypeptide hormone which is synthesized, 
stored and secreted by the ß-cells of pancreatic islets of Lan-
gerhans and which plays a vital role in glucose homeostasis. 
The ß-cells possess a sophisticated glucose-sensing system, and 
insulin secretion by these cells is a highly regulated process 
(review [2]). The three major target tissues for insulin action 
are muscle, liver and adipose tissue. Besides stimulating the 
uptake, utilization and storage of glucose (i.e. as glycogen), 
insulin action affects several other processes at the cellular 
level such as amino acid uptake, lipogenesis/lipolysis, Na+ , 
K+ pumps, protein synthesis, gene expression, DNA synthesis 
and apoptosis (review [3]). 
1.2. Insulin receptor and signaling 
Insulin action is mediated by the insulin receptor (IR) 
which belongs to the family of membrane receptor tyrosine 
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kinases. It is composed of two subunits, designated a and ß, 
that assemble into a heterodimeric α2β2 structure. Ligand 
binding to the oc-subunits results in the autophosphorylation 
of certain tyrosine residues of the ß-subunit and activation of 
the tyrosine kinase. One unique feature of the signaling mech-
anism used by IR is that its activated tyrosine kinase phos-
phorylates adaptor or docking proteins, such as IRS-1, IRS-2, 
Gabi and She, which subsequently recruit various SH2-do-
main-containing effector proteins leading, for instance, to the 
activation of the MAP kinase or the PI-3 kinase pathways 
(reviews [4,5]). Some effector proteins can also bind directly 
to the cytoplasmic domain of IR. The links at the molecular 
level between the different pathways that are activated and the 
biological effects obtained in response to insulin are still 
poorly understood. 
1.3. Potential diabetogenes 
NIDDM is considered today as a complex syndrome. Mo-
lecular defects in different sets of genes would lead to the large 
spectrum of pathophysiologies seen in this heterogeneous dis-
ease (reviews [1,6]). In this respect, one could think of muta-
tions in a variety of genes that could impair insulin action or 
ß-cell function. Table 1 presents a non-exhaustive list of such 
potential diabetogenes. Much effort is being devoted to re-
search focused on the search for candidate genes for NIDDM 
(reviews [7,8]). Since a limited number of animal models exist 
for NIDDM research (review [9]), the development of geneti-
cally engineered mice in which the effects of altered expression 
of a single gene or a set of genes could be studied in a sys-
tematic manner appears very compelling. 
2. Altering the mouse genome 
A brief outline of methods used for generating transgenic 
and 'knock-out' mice is depicted in Fig. 1. Transgenic mice 
are usually designed to examine the effects of overexpressing a 
specific gene (wild-type or mutated). The normal expression of 
an endogenous gene can also be inhibited in transgenic mice 
which produce an antisense RNA or a ribozyme directed 
against that gene. The gene-targeting approach generates mu-
tant mice with specific genes disrupted. This approach also 
makes it possible to introduce point mutations in a gene of 
interest or to perform tissue-specific gene disruption with the 
use of site-specific recombination systems (i.e. the Cre/loxP 
system). Alternatively, the combination of transgenic and 
knock-out mice can be used to generate mice in which the 
expression of disrupted genes could be reconstituted in specific 
tissues or the effects of gene mutations could be studied in the 
absence of endogenous protein. Genetically engineered mice 
represent today powerful tools for studies in molecular med-
icine. The transgenic mouse approach has been used for a 
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Fig. 1. Transgenic and gene-targeting approaches in the mouse. A: 
Transgenic mice are produced by microinjecting the DNA construct 
into male pronucleus of zygotes that are reimplanted into foster 
mothers. Founder transgenic animals in the progeny are identified 
by testing for the presence of the transgene in the genomic DNAs 
and mated with non-transgenic animals. The transgenic Fl animals 
are used for testing transgene expression and for establishing a line. 
B: The structure of the wild-type allele for the targeted gene of the 
replacement vector and of the recombinant allele after homologous 
recombination are shown. The targeting vector contains neo (neo-
mycin phosphotransferase gene) and Ik (thymidine kinase gene from 
herpes simplex virus type 1) cassettes that allow positive and nega-
tive selection in the presence of G418 and Ganciclovir, respectively, 
as well as regions of 5'- and 3'-homologies. After electroporation 
into male embryonic stem (ES) cells (derived from mouse strain 129 
carrying the dominant agouti fur coat color gene), resistant clones 
that have undergone the right homologous recombination event are 
identified (i.e. by Southern blot analysis using appropriate restriction 
enzymes and probes or by PCR using appropriate primers). Recom-
binant ES cells are injected into blastocysts (i.e. from strain 
C57B1/6) which are reimplanted into foster mothers, and generate 
chimeras (composite fur coat color) at term. The whole game con-
sists in getting male germline chimeras which give agouti pups in 
the progeny when crossed with C57B1/6 females for instance. Agouti 
animals are genotyped to identify heterozygous mutants which when 
intercrossed give homozygous mutant mice. 
decade to develop animal models for NIDDM (review [10]). 
More recently, application of the gene-targeting approach (re-
view [11]) has revived interests in mice as animal models for 
diabetes. 
3. Manipulating insulin action in the mouse 
3.1. Insulin receptor 
Transgenic mice expressing human IR cDNA under the 
control of the myosin light chain-2 (MLC-2) gene promoter/ 
enhancer have been generated [12]. Although the receptor 
number in skeletal muscle was increased, no significant 
changes in basal glucose and insulin levels were detected. 
However, glucose and insulin level regulation was affected 
after intraperitoneal glucose load. Other transgenic mice ex-
pressing human IR cDNA encoding a tyrosine kinase-defi-
cient form under the control of the native promoter did not 
show any glucose intolerance, probably due to limited expres-
sion of the transgene [13]. Expression of human IR cDNA 
encoding another tyrosine kinase-deficient dominant negative 
form in skeletal and cardiac muscle was achieved in transgenic 
mice using the muscle creatine kinase gene promoter [14]. This 
resulted in impaired insulin-stimulated IR tyrosine kinase ac-
tivity in muscle along with defective activation of downstream 
signaling proteins such as IRS-1 and PI-3 kinase [15]. Insulin-
dependent glucose uptake and metabolism in skeletal muscle 
were impaired [16]. Stimulation of MAP kinase and p90rsk 
were not detectable, whereas activation of p70S6k and glyco-
gen synthetase were preserved [17]. Finally, expression in 
transgenic mice of the extracellular domain of human IR in 
a soluble form using the mouse transferrin gene promoter 
resulted in altered glucose homeostasis [18]. 
More recently, mice carrying a null mutation in the IR gene 
have been reported [19,20]. Heterozygous animals showed 
normal glucose tolerance and were fertile. Homozygous 
pups were near normal at birth but rapidly developed meta-
bolic disorders, such as hyperglycemia and elevated plasma 
triglyceride levels, which led to diabetic ketoacidosis and he-
patic steatosis. The hyperglycemia also resulted in hyperinsu-
linemia. The glycogen content in the liver was reduced. 
Marked postnatal skeletal muscle hypotrophy and growth re-
tardation were observed, and the IR-deficient pups finally died 
within 1 week after birth. 
Insulin and insulin-like growth factors (IGF-l/IGF-2) and 
their receptors are structurally very similar and lead to some 
common as well as specific biological effects [21]. Genes en-
coding IGF-1 or IGF-2 or the IGF-1 receptor have already 
Table 1 
Proteins encoded by potential diabetogenes 
Proteins involved in insulin action 
The insulin receptor 
Substrates of the receptor tyrosine kinase 
Insulin-responsive enzymes of intracellular metabolism 
Insulin-responsive effectors controlling gene expresssion 
Enzymes of metabolic processes controlling glucose uptake 
and output by the liver 
Proteins controlling the secretion of counterregulatory 
hormones 
Transcription factors controlling the expression of such 
diabetogenes, etc. 
Proteins involved in ß-cell function 
Proteins involved in the glucose sensing mechanism: 
transporter, glucokinase, other enzymes involved in ß-cell 
glucose metabolism 
Factors determining ß-cell sensitivity to nonglucose 
secretagogues 
Factors of processes controlling ß-cell growth and 
regeneration 
Proteins of processes involved in insulin synthesis and 
release 
The insulin molecule itself 
Factors controlling transendothelial transport of insulin, etc. 
Adapted from [6]. 
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been inactivated in the mouse [22-24]. Since these different 
ligands are known to bind to and activate the heterologous 
receptor, mice carrying single, double or multiple mutations 
will allow examination of the question of whether and to what 
extent insulin and IGF-1 receptors and their ligands can sub-
stitute for each other. 
3.2. IRS-1 
Homozygous mice carrying a null mutation in the IRS-1 
gene showed intra-uterine and postnatal growth retardation 
[25,26]. However, IRS-1-deficient mice did not present any 
major metabolic disorders, indicating that IRS-1 can be re-
placed by other homologous docking proteins of insulin sig-
naling. 
3.3. Hexokinase II 
Phosphorylation of glucose to glucose-6-phosphate, the first 
step of glucose metabolism, is performed by hexokinase. Its 
major isoform present in insulin-responsive tissues is hexoki-
nase II. Transgenic mice overexpressing human hexokinase II 
using the promoter for the rat muscle creatine kinase gene 
have been produced [27]. These mice were unaffected for 
oral glucose tolerance, intravenous insulin tolerance and in 
their insulin and lactate levels. 
3.4. GLUT4 and GLUT1 
Glucose transport across the plasma membrane is facili-
tated by glucose transporters that represent a large family 
comprising GLUT1 to GLUT5 and GLUT7. These different 
transporters have different biochemical properties and corre-
spond to different gene products differentially synthesized in 
various tissues. GLUT4, mainly synthesized in muscle and 
adipose cells, is particular in that it is present in intracellular 
vesicles that are translocated to the plasma membrane in re-
sponse to insulin. A number of transgenic mice have been 
produced which overexpress the human, mouse or rat 
GLTU4 gene or the corresponding cDNA using either its 
own promoter or the promoters for the MLC-2 gene, the 
aldolase A gene (skeletal muscle-specific) or the adipocyte 
P2 (aP2) gene (specific for adipose tissue). Overexpression of 
GLUT4 under its own promoter resulted in increased whole-
body insulin action [28-35] with an obesity that usually ac-
companies a high-fat diet but glycemic control was not im-
paired [36]. In the same line, overexpression of GLUT4 re-
duced hyperglycemia and improved glycemic control in 
diabetic dbldb mice which carry a mutated leptin receptor 
gene [37], and overexpression of GLUT4 using the aP2 pro-
moter resulted in increased adiposity in transgenic mice 
[38,39]. In skeletal muscle, overexpression of GLUT4 resulted 
in glycogen accumulation [40,41], and overexpression of 
GLUT1 reduced blood glucose levels [42^14]. 
Recently, targeted disruption of the GLUT4 gene was 
achieved and gave surprising results [45]. GLUT4-deficient 
mice did not develop diabetes as severe as one might have 
expected. Only male animals showed a mild fasting hypogly-
cemia and slight postprandial hyperglycemia. However, insu-
lin resistance existed in both females and males as evidenced 
by postprandial hyperinsulinemia and impaired glucose toler-
ance tests. In addition, a number of disorders in lipid metab-
olism were observed such as raised serum levels of lactate, free 
fatty acids and ß-hydroxybutyrate in the fasting state and 
marked reduction in fat tissue deposits. Finally, GLUT4-de-
ficiency resulted in growth retardation and reduced longevity 
(5-6 months) due to cardiac hypotropy. 
3.5. PEPCK 
Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes 
the first step of gluconeogenesis in the liver. Transgenic mice 
expressing the rat PEPCK gene under its own promoter have 
been generated [46]. These animals presented with fasting hy-
perglycemia, reduced hepatic glycogen storage, reduced 
GLUT4 gene expression in muscle and altered glucose toler-
ance. 
3.6. G\a2 
The G protein, G;a2, has been implicated in the inhibition 
of adenylcyclase. Transgenic mice producing an antisense 
RNA directed against G ia2 mRNA have been generated. 
These mice express an antisense sequence inserted in the 5'-
untranslated region of rat PEPCK gene. Gi„2 gene expression 
was down-regulated in adipose tissue and liver, which resulted 
in hyperinsulinemia, impaired glucose tolerance and resistance 
to insulin affecting, for instance, glucose transporter activity 
and recruitment, counterregulation of lipolysis and activation 
of glycogen synthesis [47]. Gia2 deficiency increased the activ-
ities of protein tyrosine phosphatases and reduced IRS-1 
phosphorylation. 
3.7. Manipulating adiposity 
The mechanisms of insulin resistance associated with obe-
sity, a major risk factor for NIDDM, are still poorly under-
stood (review [48]). Recently, a few studies have attempted to 
manipulate adiposity in mice. Transgenic mice expressing a 
toxigene, encoding the diphteria toxin A chain, under the 
control of the aP2 gene promoter or the promoter for the 
mitochondrial uncoupling protein gene (brown fat tissue-spe-
cific) were obtained [49-51]. Overexpression of glycerol 3-
phosphate dehydrogenase gene in transgenic mice was 
achieved using its own promoter [52]. Finally, targeted disrup-
tion of the gene encoding Rnp, one of the regulatory subunits 
of cAMP-dependent protein kinase A, has been performed 
[53]. These mice have abnormal brown and/or white fat tissues 
and will be useful models for studying the contribution of fat 
tissue in glucose homeostasis and the obesity associated insu-
lin resistance leading to NIDDM. 
4. Creating ß-cell dysfunction in the mouse 
As noted above, NIDDM patients present with ß-cell de-
fects in addition to insulin resistance, and it is still a matter of 
debate as to which might be the primary cause of NIDDM 
[54]. In this respect, transgenic mouse models in which ß-cell 
function is impaired are potentially important to consider. 
4.1. Insulin 
The first transgenic mice expressing the human insulin gene 
under the control of its own promoter had normal insulin 
levels and glucose homeostasis [55,56]. Although total insulin 
mRNA levels could be elevated 2-fold or more, total serum 
and pancreatic insulin levels remained normal indicating the 
existence of post-transcriptional regulation for insulin produc-
tion [57]. Two transgenic mouse lines carrying multiple copies 
of the human insulin gene were later reported which became 
hyperinsulinemic and showed glucose intolerance [58]. Trans-
102 
genic mice for mutated human insulin genes were also pro-
duced. It was shown that a HisBlO to Asp mutation resulted 
in high levels of proinsulin secretion via the unregulated con-
stitutive pathway [59]. Constitutive proinsulin release was also 
reported for SerB9 to Asp and ThrB27 to Glu mutations [60]. 
4.2. Glucokinase 
A specific isoform of hexokinase, hexokinase IV or gluco-
kinase (GK), is present in ß-cells and liver, and has been 
proposed to act in ß-cells in glucose sensing. In transgenic 
mice producing an antisense RNA encompassing a ribozyme 
element under control of the rat insulin II gene promoter 
(PinsiiX the GK activity in islets was reduced and insulin re-
lease in response to glucose from in situ-perfused pancreas 
was reduced [61]. However, plasma glucose and insulin levels 
remained normal. In another study, transgenic mice produc-
ing antisense RNA to the glucokinase gene under control of 
the human insulin gene promoter showed glucose intolerance 
that was mouse strain-dependent [62]. Transgenic mice over-
expressing yeast hexokinase B under control of Pinsn showed 
increased insulin secretion and reduced blood glucose [63]. It 
was subsequently reported that overexpression of yeast hexo-
kinase B caused significant pancreatic depletion of insulin [64]. 
The breeding of these mice overexpressing hexokinase B with 
transgenic mice made diabetic by overexpression of a chicken 
calmodulin gene in ß-cells [65] transiently improved their dia-
betic symptoms. However, this protection was short-lived and 
did not protect against insulin depletion of ß-cells. 
More recently, mice carrying a disrupted GK gene have 
been generated [66-68]. Heterozygous animals showed mild 
diabetes. They were hyperglycemic with reduced capacity to 
secrete insulin and showed glucose intolerance. In their liver, 
glucose production persisted even under hyperglycemic and 
hyperinsulinemic conditions and glycogen content was re-
duced. Homozygous pups became extremely hyperglycemic 
and developed severe diabetes. The levels of cholesterol and 
triglycerides in the serum were elevated. Absence of GK in the 
liver resulted in reduced glycogen stores and in steatosis. GK-
deficient pups were growth retarded and survived 3-5 days 
after birth. Reconstitution of GK activity using transgenic 
mice expressing GK cDNA in ß-cells using Pinsii rescued the 
lethal phenotype. 
4.3. GLUT2 
GLUT2 has also been proposed to be part of the ß-cell 
glucose sensing machinery. GLUT2 gene expression in ß-cells 
could be reduced by 80% at the protein level in transgenic 
mice producing antisense RNA to GLUT2 using Pinsn [69]. 
Such mice were hyperglycemic and had impaired glucose tol-
erance tests. However, in transgenic mice expressing the hu-
man oncogene [Val12]HRAS using Pinsn which resulted in 
down-regulation of GLUT2 in ß-cells, glucose homeostasis 
remained unaffected in 2-month-old animals [70]. 
4.4. IAPP 
Islet amyloid polypeptide (IAPP) is a normal constituent of 
ß-cells. Transgenic mice expressing the human or rat IAPP 
gene using Pinsi, Pinsii or the human insulin gene promoter 
had increased IAPP levels in their blood [71-74]. In some 
reports, no amyloid deposits, characteristic of pathological 
states, were detected in the islets up to 7 months of age 
whereas accumulation of nonfibrillar human (but not rat) 
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IAPP mass was reported in perivascular spaces in one study 
[74]. The animals were normoglycemic and normoinsulinemic. 
5. Conclusion 
It appears that both insulin action and ß-cell function can 
be manipulated by altering the expression of many genes. 
Transgenic and gene-targeting approaches, therefore, offer 
great potential for further developing mouse models in which 
the effects of defined alterations in a set of genes could be 
examined. The study of such genetically engineered mice will 
help understanding the molecular basis of complex patho-
physiologies in different kinds of NIDDM in humans. A sys-
tematic analysis of potential diabetogenes might also help the 
search for candidate genes in human disorders. Such mutant 
mice could also be used to test therapeutic strategies. 
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